Ex Vivo Gamma Delta T Cell Populations

text
September 15, 2022

Inventors

Katharina Bergerhoff, Oxana Polyakova, Oliver Nussbaumer

Assignees

GammaDelta Therapeutics

Abstract

The invention relates to ex vivo methods of modulating Vδ1 T cells using anti-Vδ1 antibodies or fragments thereof.

CovalX Technology Used

Epitope Mapping
XL-MS

Contact our Scientific Team to Start the Conversation

Request A Call
Source
https://patents.google.com/patent/US20220290101A1
Back
Categories : Patents, Epitope Mapping
text
PREVIOUS : Novel Antibodies to a gamma variable 4 (Vγ4) chain of a γδ T cell receptor (TCR)
NEXT : Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis
text